Medicare AdvantagePrior AuthLow impact
Triptodur™ (triptorelin) (Revised)
Humana·KY · Pediatrics, Endocrinology·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana has issued a revised prior authorization policy for Triptodur (triptorelin) intramuscular suspension, effective January 1, 2026, for Medicare and Medicaid Kentucky plans. The policy requires prior authorization for treatment of central precocious puberty in pediatric patients 2 years and older, with approval lasting the plan year duration.
Action Required
By January 1, 2026: Billing team must ensure prior authorization is obtained before prescribing or billing for Triptodur (triptorelin) intramuscular suspension for pediatric patients with central precocious puberty on Humana Medicare and Medicaid Kentucky plans. Verify patient meets criteria of having a diagnosis of central precocious puberty. Claims without prior authorization will be denied.